Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo.

ABSTRACT:

Background

HER2-targeted therapies have revolutionised the treatment of HER2-positive breast cancer. However, de novo resistance or the emergence of acquired resistance is a persistent clinical problem. Here we report that neratinib, an irreversible pan-HER inhibitor, in combination with the multi-kinase inhibitor dasatinib, currently used to treat certain leukemias, has strong anti-proliferative effects against models of HER2-positive breast cancer that are innately resistant to trastuzumab or have acquired resistance to neratinib.

Methods

Neratinib plus dasatinib was examined in a panel of 20 breast cancer cell lines, including HER2-positive, estrogen-receptor-positive, triple negative, and acquired HER2-targeted therapy resistant models. Drug effects on migration and apop

SUBMITTER: Conlon NT 

PROVIDER: S-EPMC11396364 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature